#USA #Portland #AI Drug Discovery #Araceli Biosciences #Endeavor Live Cell

Araceli Biosciences Introduces Endeavor® Live Cell

Araceli Biosciences, a leader in advanced imaging solutions for drug discovery, has just announced the launch of its latest innovation, Endeavor® Live Cell. This cutting-edge platform aims to revolutionize the way researchers conduct kinetic imaging, offering unprecedented speed and efficiency for AI-driven drug discovery processes.

In the ever-evolving landscape of pharmaceutical research, traditional methodologies often fall short when it comes to capturing dynamic biological events. The new Endeavor® Live Cell addresses this need by allowing rapid kinetic imaging across entire 1536-well plates. This technology empowers scientists to observe cellular behavior as it happens, rather than relying solely on endpoint measurements. As noted by Matt Beaudet, President and CEO of Araceli Biosciences, "Our goal is not merely to enhance imaging speed; we are dedicated to providing the high-quality biological data essential for modern drug discovery."

The Endeavor® Live Cell is built to accommodate various applications, especially those requiring real-time observations of cellular responses. This includes monitoring compound responses, assessing cell health and viability, facilitating phenotypic screening, and tracking the growth of organoids and spheroids. The rapid imaging capability, with approximately four-minute timepoints across full plates, allows researchers to work within ultra-high-throughput workflows, where consistency and automation compatibility are vital.

To develop this powerful system, Araceli partnered with Okolab, a company renowned for its expertise in live cell incubation and environmental control. Lara Petrak, Director of Sales for Okolab USA, shared her enthusiasm for the collaboration saying, "Combining our reliable environmental control with Araceli's fast and scalable imaging platform provides scientists with a robust tool to investigate dynamic biological systems across extensive screening campaigns."

As AI technologies advance, the industry's reliance on high-quality, consistent cellular data has never been greater. The integration of Endeavor® Live Cell into Lab-in-the-Loop workflows marks a significant step forward for researchers aiming to harness the full potential of AI in drug discovery. With this system, Araceli is set to bolster its position as a vital provider of imaging infrastructure for researchers engaging in Lab-in-the-Loop experimentation.

Additionally, Endeavor® Live Cell's compatibility with various assays—and its quick adaptability to changing experimental requirements—positions it as a thought leader in the field. This new launch is expected to aid in speeding up the timeframe for drug discovery, potentially bringing new therapies to the market faster than previously possible.

In conclusion, with Endeavor® Live Cell, Araceli Biosciences is not just expanding their imaging capabilities; they are paving the way for the future of drug discovery. By prioritizing speed, accuracy, and robust data generation, this trailblazing product is sure to make a lasting impact in the realm of scientific research. Researchers keen on exploring this new frontier can find more information about the Endeavor® Live Cell and its applications at aracelibio.com.